Trial · NCT00174980
Study of Oxycyte in Severe Closed Head Injury
NCT00174980, Phase 2, Terminated, Tenax Therapeutics, Inc.; results first posted 2026-02-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Oxycyte in Severe Closed Head Injury. Trials, record NCT00174980. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00174980
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Oxycyte in Severe Closed Head Injury
- NCT number
- NCT00174980
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Tenax Therapeutics, Inc.
- Conditions
- Traumatic Brain Injury
- Interventions
- Oxycyte
- First posted
- 2005-09-15
- Last updated
- 2026-02-24
- Results first posted
- 2026-02-24
- Limitations and caveats
- This study involved a sample size of just nine patients, with multiple concomitant injuries and medications, results must be regarded as provisional.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Brain Dialysate Concentration Data | 40 hours |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Brain Dialysate Concentration Data | 40 hours | microM/L | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Brain Dialysate Concentration Data | Oxycyte, Perfluorocarbon | brain dialysate glucose concentration | 800 | Standard Deviation 518 | microM/L |
| Brain Dialysate Concentration Data | Oxycyte, Perfluorocarbon | brain dialysate lactate concentration | 1066 | Standard Deviation 299 | microM/L |
| Brain Dialysate Concentration Data | Oxycyte, Perfluorocarbon | brain dialysate glutmate concentration | 13.48 | Standard Deviation 10.8 | microM/L |
| Brain Dialysate Concentration Data | Oxycyte, Perfluorocarbon | brain dialysate pyruvate concentration | 30.54 | Standard Deviation 18.25 | microM/L |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oxycyte, Perfluorocarbon | 9 | |
| Overall Study | COMPLETED | Oxycyte, Perfluorocarbon | 7 | |
| Overall Study | NOT COMPLETED | Oxycyte, Perfluorocarbon | 2 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | infection | Respiratory, thoracic and mediastinal disorders | Oxycyte, Perfluorocarbon | 6 | 9 | 6 |
| other | infection | Renal and urinary disorders | Oxycyte, Perfluorocarbon | 2 | 9 | 2 |
| other | thrombocytopenia | Blood and lymphatic system disorders | Oxycyte, Perfluorocarbon | 4 | 9 | 4 |
| other | elevated liver function tests | Hepatobiliary disorders | Oxycyte, Perfluorocarbon | 7 | 9 | 7 |
| other | anemia | Blood and lymphatic system disorders | Oxycyte, Perfluorocarbon | 4 | 9 | 4 |
| other | hemoglobin low | Blood and lymphatic system disorders | Oxycyte, Perfluorocarbon | 4 | 9 | 4 |
| serious | Injury, poisoning and procedural compliactions | Injury, poisoning and procedural complications | Oxycyte, Perfluorocarbon | 1 | 9 | 1 |
| serious | Cardiac disorders | Cardiac disorders | Oxycyte, Perfluorocarbon | 1 | 9 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oxycyte, Perfluorocarbon | ||
| Total, other adverse events | Oxycyte, Perfluorocarbon | 9 | 9 |
| Total, serious adverse events | Oxycyte, Perfluorocarbon | 2 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00174980
GET https://conductscience.org/api/trials/v1/NCT00174980/registered